Clinical trial NCT01049399: Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy
Official title: A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112, a GSK-3 Inhibitor, Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Progressive Supranuclear Palsy
Lead sponsor: Noscira SA
Sponsor class: INDUSTRY
Collaborators: name: i3 Research
First posted: 2010-01-14
Enrollment: 146
Sex: ALL
Minimum age (years): 40
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine wether NP031112 is safe and effective in the treatment of mild to moderate Progressive Supranuclear Palsy


Eligibility criteria: Inclusion Criteria:

1. Men and women with diagnosis of possible or probable PSP according to clinical criteria of National Institute of Neurologic Diseases and Stroke - the Society for PSP (Appendix 1).
2. Age of 40 to 85 years (patients over 85 years could be included after previous assessment by Investigator and approved by sponsor).
3. Brain magnetic resonance imaging (MRI) study within 24 months before Baseline visit excluding other potential causes of parkinsonism, especially cerebrovascular lesions and space occupying lesions.
4. Mild-to-moderate stage of disease severity according to score of 1 to 4 in Golbe Staging System.(Appendix 2)
5. Female patients must be surgically sterilized; at least 1 year postmenopausal (confirmed by follicle-stimulating hormone \[FSH\] \>20 international units \[IUs\]); using adequate birth control (implants, injectables, combined oral contraceptives, intrauterine contraceptive device, total sexual abstinence during the study or vasectomised partner). Male patients must be willing to use barrier contraception (condom) during the study and for 6 months after last treatment administration.

   In European arms of study female patients must be without childbearing potential.
6. Caregiver (or dedicated nurse) living in same household or interacting with patient for \>4 hours every day able to assure correct preparation and administration of study drug.
7. Patients living at home or in retirement home not requiring continuous nursing care.
8. General health status acceptable for participation in 64-week clinical trial.
9. Ability to swallow 100 mL of water suspension.
10. Any concomitant medication for PSP must be well-tolerated and unchanged for at least 1 month prior to Baseline visit and its dose and regimen should be maintained during study if there are no clinical reasons to modify it.
11. Occupational, physical, respiratory, or speech therapy is allowed but it must be stable for at least 1 month prior to screening.
12. Pharmacological treatment of any other chronic condition must be stable and well-tolerated for at least 1 month prior to screening. Analgesics, occasional per request nonsteroidal anti-inflammatory agents, and treatments for transient or emergent conditions are allowed.
13. Signed informed consent by patient and permitted prior to initiation of any study-specific procedure.

Exclusion Criteria:

1. Failure to perform screening or baseline examinations.
2. Hospitalization or change of chronic concomitant medication 1 month prior to or during screening period (apart from pre-planned hospitalization for a condition, which did not deteriorate since 1 month prior to screening period).
3. Clinical, laboratory or neuroimaging findings consistent with:

   * other primary degenerative diseases such as Parkinson's disease; dementia with Lewy bodies; corticobasal degeneration; frontotemporal dementia; multiple system atrophy; parkinsonism-dementia complex of Guam, Kii or Guadeloupe; Alzheimer's disease; amyotrophic lateral sclerosis; Creutzfeldt-Jakob Disease; Huntington's disease; Down's syndrome; etc.
   * cerebrovascular disease as major, strategic or multilacunar infarcts, or extensive white matter lesions scoring 3 in the Wahlund's scale \[Wahlund et al., 2001\].
   * other central nervous system diseases (hydrocephalus, severe head trauma, tumours, subdural haematoma or other relevant space occupying processes, etc.).
   * epilepsy.
   * other infectious, metabolic or systemic diseases affecting central nervous system (syphilis, present hypothyroidism, present vitamin B12 or folate deficiency, clinically significant serum electrolyte disturbances, juvenile onset diabetes mellitus, etc.).
4. A current Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) diagnosis of active major depression, schizophrenia or bipolar disorder.
5. Clinically significant, advanced or unstable disease that may interfere with primary or secondary variable evaluations, may bias clinical or mental assessment or put patient at special risk, such as:

   * chronic liver disease, as indicated by liver function test abnormalities (ALAT, ASAT, bilirubin or GGT out of range) positive serology for Hepatitis C, or other manifestations of liver disease
   * respiratory insufficiency
   * renal insufficiency (serum creatinine \>2 mg/dL (\>150 micromol/L) and creatinine clearance \<60 (according to Cockcroft-Gault formula)
   * heart disease (myocardial infarction, unstable angina, heart failure, cardiomyopathy within 6 months before screening).
   * bradycardia (heart beat \<50/min) or tachycardia (heart beat \>95/min)
   * episodes of unstable or uncontrolled hypertension (systolic pressure \>160 mm Hg or diastolic pressure \>100 mm Hg) or hypotension (systolic pressure \<90 mm Hg or diastolic pressure \<45 mm Hg) during 2 months prior to Baseline visit.
   * atrioventricular block (type II / Mobitz II and type III), congenital long QT syndrome, sinus node dysfunction or prolonged QTcF interval (males \>450 msec and females \>470 msec using Fridericia's formula: QTc = QT/cube root of RR).
   * uncontrolled diabetes mellitus.
   * malignant tumors within last 5 years except skin malignancies (other than melanoma) or indolent prostate cancer.
   * metastases.
6. Disability that may prevent the patient from completing all study requirements (e.g., blindness, deafness, and severe language difficulty).
7. Chronic daily drug intake of:

   * drugs metabolized by cytochrome P450 (CYP)3A4 with narrow therapeutic window (acenocoumarol, warfarin, and digitoxin)
   * anticonvulsants indicated for epileptic seizures
   * systemic anticholinergics with relevant action on central nervous system
   * acetylcholinesterase inhibitors
   * neuroleptics except quetiapine, clozapine or other atypical neuroleptics
   * nootropics such as piracetam, propentofylline, hydergine, vinpocetine, ginkgo biloba, coenzyme Q-10, idebenone and derivatives
   * centrally active anti-hypertensive drugs such as clonidine, alpha methyl dopa, guanidine, and guanfacine
   * systemic cortico-steroids or immunosuppressants
   * systemic nonsteroidal anti-inflammatory agents (except taken as occasional medication per request or acetylsalicylic acid up to 100 mg/day as an antiplatelet agent).
   * memantine, lithium, valproic acid or other GSK-3 inhibitors within 3 months prior to the Baseline visit.
8. Suspected or known history of drug abuse or excessive alcohol intake\*
9. Suspected or known allergy to any components of study treatments.
10. Enrollment in another investigational drug study within 3 months before Baseline visit.
11. Any condition, which in the opinion of Investigator makes patient unsuitable for inclusion or likely to be non-compliant.

    * More than 21 units per week for men and 14 for women; or consumption of more than 8 units in a single episode. 1 unit equals approximately 1 glass of wine, 250 ml of beer or 1 shot (25 ml) of spirit.

Primary outcomes:
measure: The change from Baseline between the 2 active study medication groups compared with the placebo group in the Progressive Supranuclear Palsy Rating Scale of Golbe
timeFrame: 52 weeks
Secondary outcomes:
measure: Number of AEs and patients with an incidence rate of ≥ 5% AEs
timeFrame: 52 weeks
measure: Change from Baseline between 2 active study medication groups vs placebo group in Modified Schwab and England Scale
timeFrame: 52 weeks
measure: Change from Baseline between 2 active study medication groups vs placebo group in Timed Up and Go Test (quantitative motor function)
timeFrame: 52 weeks
measure: Change from Baseline between 2 active study medication groups vs placebo group in cognitive function(Dementia Rating Scale-2,Frontal Assessment Battery,category and letter verbal fluency)
timeFrame: 52 weeks
measure: Change from Baseline between 2 active study medication groups vs placebo group in Starkstein Apathy Scale (behavior)
timeFrame: 52 weeks
measure: Change from Baseline between 2 active study medication groups vs placebo group in functional assessments(Unified Parkinson Disease rating Scale part II and European Quality of Life questionnaire)
timeFrame: 52 weeks
measure: Change from Baseline between 2 active study medication groups vs placebo group in Clinical Global Impression of Change
timeFrame: 52 weeks
measure: Change from Baseline between 2 active study medication groups vs placebo group in Clinical Global Impression of Severity
timeFrame: 52 weeks
Other outcomes:
Locations:
city: Fountain Valley
country: United States
facility: The Parkinson's and Movement Disorder Institute
state: California
city: Los Angeles
country: United States
facility: Department of Neurology, David Geffen School of Medicine at UCLA
state: California
city: Jacksonville
country: United States
facility: Mayo Clinic Jacksonville
state: Florida
city: Tampa
country: United States
facility: University of South Florida 5
state: Florida
city: Louisville
country: United States
facility: Division of Movement Disorders, University of Louisville
state: Kentucky
city: New Brunswick
country: United States
facility: University of Medicine and Dentistry, Robert Wood Johnson Medical School
state: New Jersey
city: Beelitz-Heilstätten
country: Germany
facility: Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson Beelitz
city: Berlin
country: Germany
facility: Humboldt Universitat Charite, Campus Virchow, Neurologisch
city: Dresden
country: Germany
facility: Universitatsklinikum Carl-Guslav-Carus, Technische Universitat Dresden, Klinik und Poliklinik fur Neurologie
city: Hannover
country: Germany
facility: Medizinische Hochschule Hannover, Neurologie 0E 7210
city: Marburg
country: Germany
facility: Zentrum fur Nervenheilkunde. Klinik fur Neurologie mit Poliklinik.
city: Tubingen
country: Germany
facility: University Hospital Tuebingen,Eberhard-Karls-Universitat, Universitatsklinikum Neurologie
city: Barakaldo
country: Spain
facility: Hospital de Cruces
city: Barcelona
country: Spain
facility: Fundació Ace
city: Barcelona
country: Spain
facility: Dpto.neurologia. H. Clinic.
city: Madrid
country: Spain
facility: Dpt. Neurologia. Hospital Ramón y Cajal.
city: Madrid
country: Spain
facility: Hospital U. La Paz
city: Madrid
country: Spain
facility: Hospital Puerta del Hierro
city: San Sebastian
country: Spain
facility: Hospital de Donostia
city: Terrasa
country: Spain
facility: Hospital Mutua Terrassa
city: Valencia
country: Spain
facility: Departement of Neurology, Hospital La Fe
city: Liverpool
country: United Kingdom
facility: The Walton Centre for Neurology and Neurosurgery NHS Trust
city: London
country: United Kingdom
facility: Reta Lila Weston Institute of Neurological Studies,Sara Koe PSP Research Centre
city: Newcastle upon Tyne
country: United Kingdom
facility: Clinical Ageing Research Unit
Study officials:
References:
citation: Hoglinger GU, Schope J, Stamelou M, Kassubek J, Del Ser T, Boxer AL, Wagenpfeil S, Huppertz HJ; AL-108-231 Investigators; Tauros MRI Investigators; Movement Disorder Society-Endorsed PSP Study Group. Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials. Mov Disord. 2017 Jun;32(6):842-852. doi: 10.1002/mds.26973. Epub 2017 Apr 24.